The RNA exosome component hRrp6 is a target for 5-fluorouracil in human cells

Mol Cancer Res. 2008 Jun;6(6):990-5. doi: 10.1158/1541-7786.MCR-07-2217.

Abstract

The drug 5-fluorouracil (5-FU) is a widely used chemotherapeutic in the treatment of solid tumors. Recently, the essential 3'-5' exonucleolytic multisubunit RNA exosome was implicated as a target for 5-FU in yeast. Here, we show that this is also the case in human cells. HeLa cells depleted of the inessential exosome component hRrp6, also called PM/Scl100, are significantly growth impaired relative to control cells after 5-FU administration. The selective stabilization of bona fide hRrp6 RNA substrates on 5-FU treatment suggests that this exosome component is specifically targeted. Consistently, levels of hRrp6 substrates are increased in two 5-FU-sensitive cell lines. Interestingly, whereas down-regulation of all tested core exosome components results in decreased hRrp6 levels, depletion of hRrp6 leaves levels of other exosome components unchanged. Taken together, our data position hRrp6 as a promising target for antiproliferative intervention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology*
  • Cell Line
  • Endogenous Retroviruses / genetics
  • Exoribonucleases / antagonists & inhibitors*
  • Exoribonucleases / genetics
  • Exosome Multienzyme Ribonuclease Complex
  • Fluorouracil / pharmacology*
  • HeLa Cells
  • Humans
  • Nuclear Proteins / antagonists & inhibitors*
  • Nuclear Proteins / genetics
  • RNA Interference
  • RNA Stability
  • RNA, Messenger / metabolism

Substances

  • Antimetabolites, Antineoplastic
  • Nuclear Proteins
  • RNA, Messenger
  • Exoribonucleases
  • Exosome Multienzyme Ribonuclease Complex
  • EXOSC10 protein, human
  • Fluorouracil